Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 162 of the 162 references it cites were found in a registry or an index.

Neoadjuvant therapy for pancreatic cancer

Abstract

Patients with localized pancreatic ductal adenocarcinoma (PDAC) are best treated with surgical resection of the primary tumour and systemic chemotherapy, which provides considerably longer overall survival (OS) durations than either modality alone. Regardless, most patients will have disease relapse owing to micrometastatic disease. Although currently a matter of some debate, considerable research interest has been focused on the role of neoadjuvant therapy for all forms of resectable PDAC. Whilst adjuvant combination chemotherapy remains the standard of care for patients with resectable PDAC, neoadjuvant chemotherapy seems to improve OS without necessarily increasing the resection rate in those with borderline-resectable disease. Furthermore, around 20% of patients with unresectable non-metastatic PDAC might undergo resection following 4-6 months of induction combination chemotherapy with or without radiotherapy, even in the absence of a clear radiological response, leading to improved OS outcomes in this group. Distinct molecular and biological responses to different types of therapies need to be better understood in order to enable the optimal sequencing of specific treatment modalities to further improve OS. In this Review, we describe current treatment strategies for the various clinical stages of PDAC and discuss developments that are likely to determine the optimal sequence of multimodality therapies by integrating the fundamental clinical and molecular features of the…

Overview

Integrity signals

Registry

Crossref · 10.1038/s41571-023-00746-1

Cites

162 of 162 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 162 references

Research works printed but not linked: 1

  1. Amin, M. B. et al. (eds) AJCC Cancer Staging Manual 8th edn (Springer, 2017).

Cited by

See all 420

Metadata

Authors
Springfeld, C., Ferrone, C. R., Katz, M. H. G., Philip, P. A., Hong, T. S., Hackert, T., Büchler, M. W., & Neoptolemos, J.
Affiliations
  • University Hospital Heidelberg (DE)
  • Cedars-Sinai Medical Center (US)
  • The University of Texas MD Anderson Cancer Center (US)
  • Wayne State University (US)
  • Harvard University (US)
  • University Medical Center Hamburg-Eppendorf (DE)
  • Heidelberg University (DE)
Corresponding author
Neoptolemos, John
Venue
Nature Reviews Clinical Oncology
Published
2023-03-17
Volume
20
Issue
5
Pages
318-337
ISSN
  • 1759-4774 (ISSN-L)
  • 1759-4782
OpenAlex
W4327697352
Cited by
377
References
162
Citations by year
2026: 76 · 2025: 129 · 2024: 125 · 2023: 46
FWCI
12.32
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Nature Reviews Clinical Oncology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Health Sciences › Medicine › Surgery › Cholangiocarcinoma and Gallbladder Cancer Studies
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › MRI in cancer diagnosis
Keywords
pancreatic ductal adenocarcinoma, neoadjuvant therapy, borderline resectable pancreatic cancer, unresectable pancreatic cancer, combination chemotherapy, induction chemotherapy, chemoradiotherapy, surgical resection, adjuvant chemotherapy, overall survival, micrometastatic disease
MeSH terms
Antineoplastic Combined Chemotherapy Protocols, Humans, Neoplasm Recurrence, Local, Pancreatic Neoplasms, Neoadjuvant Therapy, Carcinoma, Pancreatic Ductal

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Neoadjuvant therapy for pancreatic cancer. https://app.cochat.ai/papers/10.1038/s41571-023-00746-1
The paper
Springfeld, C., Ferrone, C. R., Katz, M. H. G., Philip, P. A., Hong, T. S., Hackert, T., Büchler, M. W., & Neoptolemos, J. (2023). Neoadjuvant therapy for pancreatic cancer. Nature Reviews Clinical Oncology. https://doi.org/10.1038/s41571-023-00746-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.